# Parkinson's Disease and Robot-Assisted Gait Training (RAGT)

# 1. Introduction

### Parkinson‚Äôs disease
Parkinson‚Äôs disease has a profound impact on daily life, affecting the emotional state, independence, and social interactions of patients. It has been demonstrated that movement therapies play a crucial role in the treatment of Parkinson‚Äôs patients, as they help to reduce symptoms such as tremor, rigidity, and freezing of gait. Physiotherapy for people with Parkinson‚Äôs is both costly and labor-intensive. At present, not every patient has access to such therapy, as treatment is only partially covered by basic health insurance. In practice, patients may avoid physiotherapy altogether due to financial constraints.
Parkinson‚Äôs disease is a progressive neurological disorder with varying degrees of severity and complexity. It differs from other neurological diseases primarily due to its characteristic motor decline, largely caused by the accumulation of Lewy bodies within neurons and the loss of dopaminergic neurons in the substantia nigra. The symptoms are diverse: patients may experience difficulties with walking, communication, and performing simple tasks. In addition to motor problems, non-motor symptoms such as depression, anxiety, disinhibition, and sleep disturbances are common. Patients may also struggle with eating, swallowing, and speaking. Postural instability, together with tremor, rigidity, and bradykinesia, is a hallmark of the disease. A particularly debilitating symptom is freezing of gait (FOG), in which patients suddenly ‚Äúfreeze‚Äù mid-step and remain immobile for seconds or even minutes. Unfortunately, FOG becomes more prevalent as the disease progresses [1]. The symptoms typically develop gradually, often beginning on one side of the body, significantly reducing the quality of life. Due to the motor  impairment, falls are common and can be severe. 70% of patients fall at least once per year, and 39% fall regularly. The consequences are substantial, including fractures, bruising, other injuries, hospitalizations, anxiety, and increased strain on the healthcare system [2]. Alongside pneumonia and other complications, falls are among the leading causes of death in people with Parkinson‚Äôs disease [3].
Diagnosing Parkinson‚Äôs disease can be challenging, as no specific test exists. Diagnosis is based on medical history and neurological examination. The etiology of Parkinson‚Äôs disease remains unclear. Risk cannot be attributed solely to environmental factors; rather, the disease appears to result from a complex interaction between genetic predispositions and environmental exposures, which together influence multiple cellular processes [4]. Researchers are currently investigating environmental triggers, such as exposure to certain chemicals, as well as genetic factors. In addition, they are investigating how cellular mechanisms, such as the aggregation of the protein alpha-synuclein in neurons and dopamine deficiency impairing neural communication, contribute to neurodegeneration. Meanwhile, new therapeutic approaches are under development to delay, prevent, or even reverse disease progression.



### Epidemiology
After Alzheimer‚Äôs disease, Parkinson‚Äôs disease is the second most common neurodegenerative disorder worldwide. It affects approximately seven million people globally, including one million in the United States. In industrialized countries, the prevalence is about 0.3% of the general population [5]. Parkinson‚Äôs predominantly affects older adults, with prevalence ranging from 1% among individuals over 60 to 4% among those over 80. The average age of onset is around 60 years, although 5‚Äì10% of cases occur earlier, between ages 20 and 50 years. These early cases are classified as young-onset Parkinson‚Äôs disease. Men are affected more frequently than women, with a ratio of 3:2 [5]. Between 1990 and 2015, the number of Parkinson‚Äôs patients worldwide doubled; projections estimate that by 2040 the number will nearly triple to 14 million. This expected increase is often referred to as the ‚ÄúParkinson‚Äôs pandemic‚Äù [6].
In the Netherlands, the number of patients is also increasing, partly due to an aging population. In 2017, 48,620 people were diagnosed with Parkinson‚Äôs disease: 29,466 men and 19,245 women, according to the Dutch Central Bureau of Statistics (CBS). This corresponds to 3.38 per 1,000 men and 2.21 per 1,000 women, or about 286 patients per 100,000 inhabitants. By 2025, the number of patients is expected to rise to 75,000. Regional variation exists: the highest prevalence is in Limburg (341 patients per 100,000 inhabitants), while the lowest is in Flevoland (210 per 100,000) [7].


### Treatment
The current pharmacological approach to Parkinson‚Äôs disease focuses on alleviating symptoms. With the aid of medication, patients can move and walk more easily and experience fewer tremors. At present, the most effective drug for Parkinson‚Äôs disease is levodopa, a precursor of dopamine [8]. Unlike dopamine, levodopa is able to cross the blood‚Äìbrain barrier. Once in the brain, it is enzymatically converted into dopamine. Because dopaminergic neurons in the substantia nigra are progressively lost, a dopamine deficiency develops. Levodopa can partly compensate for this deficit. A major drawback, however, is that the effectiveness of levodopa diminishes over time, resulting in reduced therapeutic benefit. The drug apomorphine can enhance levodopa‚Äôs effect and is prescribed when levodopa alone is no longer sufficient. Other drugs that may be prescribed in specific cases include dopamine agonists, MAO-B inhibitors, amantadine, and anticholinergics.
For patients with severe disease, surgical interventions such as deep brain stimulation (DBS) may be considered. DBS involves implanting electrodes in motor-control regions of the brain, which deliver electrical pulses to improve motor function [1].
In addition, various assistive devices exist to help patients cope with walking difficulties. Specially designed walkers can provide support and help overcome freezing episodes. Other aids include a seat cane, which allows patients to rest when needed, or indoor walking frames to improve safety at home. Since stair climbing can become difficult, stairlifts may also be installed, allowing patients to maintain independence and remain at home longer [1].
Parkinson‚Äôs disease is not curable. It was long assumed that slowing the disease was impossible, but there is now evidence that physical exercise has a neuroprotective effect, supporting brain health and reducing functional decline [9]. The role of the general practitioner (GP) is to recognize, diagnose, and manage new symptoms or conditions related to Parkinson‚Äôs disease. When mobility issues arise, patients are typically referred to a (specialized) physiotherapist. Exercise therapy is recommended in most clinical guidelines, including those of the Dutch College of General Practitioners (NHG) [10]. According to the Royal Dutch Society for Physical Therapy (KNGF), it is advisable for patients to contact a physiotherapist as soon as possible after diagnosis for self-management support.
In more advanced cases, such as when freezing of gait occurs, physiotherapists can offer training programs aimed at improving postural stability and gait patterns [11]. Therapy also focuses on ‚Äútransfers,‚Äù i.e., functional movements such as standing up from a chair or turning over in bed [11]. Physiotherapy helps prevent reduced activity levels, fear of movement, falls, balance problems, freezing episodes, pain, and pressure ulcers. Examples of effective activities include swimming, yoga, treadmill walking, dancing, and boxing.
Through an intake questionnaire, the specialized physiotherapist identifies the patient‚Äôs specific problems and priorities. Based on this, an individualized treatment plan is developed, which may include advice, education, exercises, and training. It is recommended that Parkinson‚Äôs patients visit a physiotherapist at least once or twice per week. A recent study from Radboud University Medical Center by Talebi et al. (2022) demonstrated that patients under the care of a specialized physiotherapist experienced 25% fewer bone fractures compared to those without specialized physiotherapy [12].



# 2. Robot-Assisted gait Training on mobility and independence in Parkinson‚Äôs patients

## PICO

**Question:** 

What is the effect of robot-assisted gait training (RAGT) on mobility and independence in patients with Parkinson‚Äôs disease compared to current treatment methods?

**PubMed search strategy:**

("Robotics" [mesh] OR robotics [tiab] OR mechanics [tiab] OR mechanization [tiab]) AND ("parkinson‚Äôs" [mesh] OR "parkinson‚Äôs" [tiab]) AND ("stability" [tiab] OR "independence" [tiab] OR "freedom" [tiab] OR "health" [tiab] OR "health" [mesh])

## Study selection

- 24 results identified  
  ‚Üí 6 excluded based on title and/or abstract  
- 18 full-text articles assessed  
  ‚Üí 16 excluded as not relevant  
- 4 studies included in the review


## Overview of RAGT studies in parkinson‚Äôs disease



| Study | Design & n | Intervention | Comparison | Primary Outcomes | Results | Conclusion | Risk of Bias |
|-------|------------|--------------|-------------|------------------|---------|------------|--------------|
| **Cepecci (2019)** | RCT, n=96 | RAGT (end-effector, G-EO System) | Treadmill training | 6MWT, 10MWT, TUG, FOG-Q | Both groups improved; RAGT +18% vs treadmill +12%. Largest effect on FOG-Q (‚àí20%). | No significant difference overall; possible added benefit of RAGT for patients with freezing of gait (FOG). | **Low risk** (robust randomization, allocation concealment, blinded assessment, complete data, no selective reporting) |
| **Picelli (2012)** | RCT, n=60 | RAGT (GT1) | Treadmill & conventional physiotherapy | 10MWT, 6MWT | RAGT and treadmill groups both improved significantly vs physiotherapy; no difference between RAGT and treadmill. | RAGT equally effective as treadmill; both superior to conventional physiotherapy. | **Low risk** (clear randomization, blinded assessor, no dropouts, full reporting) |
| **Gryfe (2022)** | RCT, n=41 | Exoskeleton (Keeogo Rehab‚Ñ¢) + exercise | Exercise without exoskeleton | SCOPA-COG, 6MWT, balance, QoL | Significant improvement in cognition (p=0.014) and 6MWT (p=0.008). | Exoskeleton training promising for cognition and endurance; larger RCTs recommended. | **Moderate risk** (open-label, some dropouts, possible selection bias from motivated participants) |
| **Carda (2012)** | RCT, n=30 | Lokomat (robot-assisted treadmill) | Treadmill training | 6MWT, 10MWT, TUG, UPDRS III | Both groups improved; treadmill showed slightly more durable/faster improvements. No significant differences. | RAGT not superior; treadmill may be more effective for sustained improvements. | **High risk** (small sample size, underpowered, potential attrition bias) |

Table 1. Overview of inlcuded articles

## Included studies on effect
___
### Study 1 ‚Äì Cepecci, M. (2019)
**_Summary_**

A randomized controlled trial (RCT) investigated the clinical effects of RAGT compared with conventional treadmill training in 96 patients with Parkinson‚Äôs disease [19]. Half received RAGT using the G-EO end-effector robot, while the other half performed treadmill walking. Both groups underwent 20 sessions of 45 minutes each.
Primary outcome measures: 6-Minute Walk Test (6MWT) [21], Timed Up and Go (TUG), 10-Meter Walk Test (10MWT), and the Freezing of Gait Questionnaire (FOG-Q).

**_Results_**

Both groups showed significant improvements across all outcomes. Endurance and walking capacity increased by 18% in the RAGT group and by 12% in the treadmill group. Motor symptoms and quality of life improved by 17% and 15%, respectively. The largest effect was seen in FOG-Q scores, which decreased by 20% in both groups. Notably, patients with freezing episodes benefited more from RAGT.

**_Assessment_**

Risk of bias was low. The sample size (n=96) provided sufficient power. Both groups improved, with no significant differences overall, but RAGT appeared more beneficial for patients with freezing of gait.
___
### Study 2 ‚Äì Picelli, A. (2012)
**_Summary_**

This RCT compared RAGT, treadmill training, and conventional physiotherapy in 60 patients with mild-to-moderate Parkinson‚Äôs disease [20]. Patients received 12 sessions (45 min, 3x/week, 4 weeks).
‚Ä¢	RAGT group (n=20): Gait Trainer GT1 (end-effector).
‚Ä¢	Treadmill group (n=20): treadmill without body weight support.
‚Ä¢	Physiotherapy group (n=20): conventional gait training.
Evaluations took place pre-treatment, post-treatment, and at 3-month follow-up. Primary outcomes: 10MWT, 6MWT.

**_Results_**

No significant difference was found between RAGT and treadmill training on primary outcomes. Both groups, however, performed significantly better than the physiotherapy group, both immediately post-treatment and at 3-month follow-up.

**_Assessment_**

Risk of bias was low. The study shows that RAGT is not superior to treadmill training of equal intensity, but both are more effective than conventional physiotherapy.
___
### Study 3 ‚Äì Gryfe, P. (2022)
**_Summary_**

This RCT compared standard Parkinson‚Äôs treatment with treatment using a wearable exoskeleton (Keeogo Rehab‚Ñ¢) [21]. Patients trained twice weekly for 8 weeks with aerobic, strength, and mobility exercises. The intervention group wore the exoskeleton during training.
Outcomes: cognition, mood, gait speed, endurance, freezing, balance, and quality of life.

**_Results_**

Significant improvements were observed in cognition (SCOPA-COG, p=0.014) and endurance (6MWT, p=0.008). The exoskeleton had positive effects on participation and cognition, and was found acceptable for patients and feasible for clinical use.

**_Assessment_**

Risk of bias was moderate. The exoskeleton group showed significant cognitive and physical gains not present in controls. Authors recommend larger RCTs to assess long-term effects and potential disease-modifying impact.
___
### Study 4 ‚Äì Carda, M. (2012)
**_Summary_**

This RCT compared RAGT using the Lokomat (robotic exoskeleton attached to treadmill) with treadmill training in 60 patients [22]. Patients trained 30 min, 3x/week for 4 weeks.

**_Results_**

After 6 months, both groups showed significant improvements in 6MWT. Average distances: treadmill group 490.95 m (95% CI: 448.56‚Äì533.34, p=0.0006); Lokomat group 458.6 m (95% CI: 417.23‚Äì499.96, p=0.01). No significant differences were found between groups. Some secondary outcomes (10MWT, TUG) improved earlier in the treadmill group.

**_Assessment_**

Risk of bias was high. Both interventions improved gait performance, but no superiority of RAGT was shown. Authors suggest larger studies may be needed to clarify differences.
___



## Assessment conclusion

We reviewed the selected studies to address our PICO question: *What is the effect of RAGT on the mobility and independence of patients with Parkinson‚Äôs disease compared to current standard treatment?*  

In three out of the four studies, no significant differences were observed between the RAGT and the control groups. However, in two studies RAGT was compared with conventional physiotherapy; in both, the RAGT group performed significantly better. In three of the four studies, the RAGT group was compared with conventional treadmill training rather than physiotherapy. Between these groups, no significant differences were reported. Based on these findings, one may conclude that RAGT is superior to physiotherapy, but not to treadmill training, in improving mobility among patients with Parkinson‚Äôs disease.  

Additionally, there are indications that RAGT may have a beneficial effect on specific symptoms, such as freezing of gait (FOG). Nonetheless, certain limitations should be acknowledged: study 3 carries a moderate risk of bias, and study 4 a high risk of bias. In study 4, group differences needed to exceed 20% to be considered statistically significant, which may have led to smaller effects being overlooked.  

It is noteworthy that across all studies, the RAGT groups performed at least as well as the control groups. Therefore, the question is not only whether RAGT improves outcomes, but also whether it can serve as a sustainable future treatment option. Such an approach may reduce the physical workload of physiotherapists, decrease the number of hours required per patient, and increase accessibility for a larger number of patients.



# 3. Barriers and facilitators of the innovation

| Type / Stakeholder        | Healthcare Professionals                                         | Patients / Patient Organizations                                   | Insurers                                        | Government                                 |
|---------------------------|------------------------------------------------------------------|-------------------------------------------------------------------|------------------------------------------------|-------------------------------------------|
| üî¥ Barrier                | Lack of knowledge<br>Willingness                                   | Willingness<br>Interaction with physiotherapist                   | Cost of machine + maintenance                 | Cost of machine + maintenance             |
| üü° To be determined       | Shortage of staff<br>Workload                                      | Personalized attention<br>Patient experience                       | Treatment costs<br>Required healthcare personnel | Treatment costs<br>Required healthcare personnel |
| üü¢ Facilitator            | Specialization of healthcare and allied health professionals      | Safety<br>Access to physiotherapist                                 | ‚Äî                                              | Fall prevention                           |

Table 2: Facilitating and hindering factors categorized by stakeholder. Red: hindering factor, yellow: yet to be determined whether this is a facilitating or hindering factor through an RCT, green: facilitating factor.


## Important barriers and considerations for the implementation of RAGT

### Cost of treatment and cost-effectiveness
Convincing insurers and governmental bodies to support the implementation of Robot-Assisted Gait Training (RAGT) requires a multifaceted approach that demonstrates its effectiveness, cost-effectiveness, and benefits for patients. By engaging with healthcare providers, patient associations, and presenting strong arguments in favor of RAGT implementation, it becomes possible to persuade insurers and policymakers to invest in this form of neurorehabilitation and ensure accessibility for those who need it.
Insurers will primarily assess both the clinical effectiveness of RAGT and its impact on overall healthcare costs. Governments, in turn, will consider its effectiveness in terms of patient outcomes, as well as its potential to reduce long-term healthcare expenditures. RAGT provides additional benefits, such as consistent and precise monitoring of patient progress and a reduced risk of injury.
The Dutch government has explicitly expressed its intention to prioritize fall prevention in the coming years. Falls among older adults currently account for nearly ‚Ç¨1 billion annually in healthcare costs in the Netherlands. According to the Dutch Healthcare Institute, individuals over 65 fall at least once per year on average [3]. Specific fall-prevention programs targeting Parkinson‚Äôs patients are urgently needed. Since exercise therapy has been shown to reduce fall risk, RAGT could play a pivotal role in this context. However, for this to be feasible, physiotherapy or mobility training must be included in the standard basic health insurance package for Parkinson‚Äôs patients, rather than being reimbursed only after the 21st session.
At present, robot-assisted rehabilitation therapy is not widely available. While some rehabilitation centers already have access to robotic devices, this remains the exception rather than the rule. Broader implementation will therefore require significant investment in acquiring such equipment. Not all physiotherapy practices will have the financial means or physical space to accommodate (multiple) robots.

### Patient acceptance
Parkinson‚Äôs patients currently receiving conventional physiotherapy may not immediately embrace a novel therapeutic modality. RAGT sessions differ in part from traditional physiotherapy, and this change may require adjustment. Nevertheless, with the projected rise in healthcare costs and the growing shortage of healthcare professionals, greater reliance on technology such as RAGT will become inevitable. RAGT has the potential to optimize efficiency: one physiotherapist could supervise several patients during robot-assisted training, whereas conventional gait training may require two therapists for a single patient. In the future, patients will increasingly be referred to specialized, centrally located rehabilitation centers capable of treating multiple Parkinson‚Äôs patients simultaneously. This implies that treatment efficiency will become an integral aspect of care. Patients may undergo therapy in group settings, supported by multiple therapists circulating between them. Progress will be digitally recorded, as RAGT devices provide integrated data collection systems.

### Knowledge gaps among healthcare professionals
The effectiveness of RAGT is not solely determined by the degree of robotic support during walking. Multiple parameters‚Äîsuch as body weight support, robotic assistance levels, and treadmill speed‚Äîinteract with one another and influence treatment outcomes. The choice of parameter settings directly affects both the quality and intensity of training [23]. Additionally, treatment protocols‚Äîincluding total training hours, session frequency, and duration‚Äîplay a decisive role in recovery [24]. Different combinations of training parameters and treatment protocols can significantly influence training intensity and overall therapeutic results. For this reason, it is crucial that therapists receive adequate training in order to make informed decisions regarding the appropriate parameter configurations and treatment protocols.

# 4. Implementation Strategy
### Costs of treatment; how to convince government and insurers

To investigate the cost-effectiveness of RAGT, we reviewed several studies: Carpino, G. (2018) examined the effectiveness and costs of robot-mediated lower limb rehabilitation. Different types of robots were assessed and compared with conventional therapy. The study evaluated the effectiveness of ‚Äúoperational machines‚Äù versus ‚Äúwearable robots.‚Äù The authors concluded that RAGT using operational machines was the most cost-effective method for lower limb rehabilitation. Therapy with wearable robots was found to be 2.38 times more effective compared to conventional therapy, whereas therapy with operational machines was 2.45 times more effective compared to conventional therapy. Treatment costs were lowest for patients treated with operational machines, in comparison with both conventional therapy and wearable robot therapy.
One explanation for the difference between robot types is that wearable robots are significantly more expensive to purchase than operational machines. For instance, a Lokomat¬Æ (wearable robot) costs approximately ‚Ç¨330,000, while a Gait Trainer GT I (operational machine) costs around ‚Ç¨30,000.
There are currently few high-quality cost-evaluation studies on RAGT implementation. To provide additional insights into cost differences between conventional and robot-assisted training, we also included a study on upper limb rehabilitation after stroke. Wagner T. et al. investigated the cost-effectiveness of robot-assisted upper-limb training compared with conventional physiotherapy in stroke patients. After 36 weeks of therapy, average patient care costs in the intervention group (n=49) were $17,831, compared to $19,746 in the control group receiving intensive conventional therapy (n=50). No significant difference in quality of life was found between the two groups. However, the study suggested that the additional costs of robotic devices were offset by reduced healthcare utilization in the robot group. This indicates that robot-assisted therapy may help reduce overall healthcare costs in neurorehabilitation after stroke.
In conclusion, RAGT appears to be potentially more cost-effective than conventional therapy, as it requires fewer staff hours per patient. However, its cost-effectiveness is strongly dependent on the type of robot used.
From a policy perspective, it would be sensible for the government to emphasize fall prevention strategies to reduce the risk of falls among older adults. Parkinson‚Äôs patients, who have a particularly high fall risk, should be explicitly included in such initiatives. Physiotherapy or movement therapy should be covered by the basic healthcare insurance package. This does not necessarily mean that all physiotherapy should be fully reimbursed; rather, RAGT training could be categorized separately, for example under ‚Äúrehabilitation therapy.‚Äù Rehabilitation care following hospital admissions is already reimbursed under the basic package.
With RAGT, multiple patients can be treated simultaneously, and the robots are safe enough to allow patients to be left unsupervised for short periods. This helps contain rising healthcare costs and relieves pressure on healthcare providers. Furthermore, as RAGT reduces fall risk, it aligns well with government fall-prevention policies.
Because robotic rehabilitation therapy is not yet widely available, initial implementation should focus on equipping specialized (centrally located) treatment centers, such as hospitals or rehabilitation clinics, with this technology. For example, Radboudumc currently operates a Parkinson and Movement Disorders Expertise Center, and Den Ooiman, a care facility of Sensire, provides rehabilitation for community-dwelling Parkinson‚Äôs patients. These institutions have the space and financial resources to invest in such equipment and to train staff in its use.


### How to convince the patient

The healthcare sector is undergoing continuous change, often accompanied by new interventions and treatments. Many of these innovations contribute to improving patients‚Äô quality of life and advancing the quality of care. However, some new interventions are complex, leading to limited patient knowledge and trust in the added value of such innovations.
The primary goal of robot-assisted gait training (RAGT) is to improve the independence of patients with Parkinson‚Äôs disease. RAGT helps patients walk more effectively and perform daily tasks, thereby enhancing their sense of self-worth and confidence. By enabling patients to walk better‚Äîor relearn walking‚Äîthey regain a sense of autonomy. This, in turn, reduces frustration and anxiety, which are common among Parkinson‚Äôs patients. Furthermore, patients are more likely to reach their rehabilitation goals sooner, which positively impacts mood and emotional well-being.
Fundar√≤ C. et al. (2018) investigated the psychosocial impact of RAGT on patients with neurological conditions in a rehabilitation setting, including Parkinson‚Äôs patients. The researchers found a positive association between RAGT and improved well-being, adaptability, and self-esteem.
To increase patient acceptance, it is essential to engage with Parkinson‚Äôs patient associations to provide information on RAGT and its potential impact. Feedback from patients should be actively sought, as they may contribute valuable suggestions to improve the intervention.
Patients can be informed through educational leaflets available in general practitioner practices, hospitals, or nursing homes. Additionally, accessible online resources should be developed to highlight the benefits of RAGT. Transparency about the safety, effectiveness, and efficiency of RAGT is crucial during both the introduction and implementation phases. Continuous evaluation of RAGT should be carried out with relevant stakeholders to ensure credibility and trust.

### How to train healthcare professionals

At present, there is no optimized combination of training parameters and treatment protocols for RAGT. The most effective training strategy is likely to vary depending on the patient and the specific condition. Initially, an assessment should determine the patient‚Äôs baseline ability to walk, alongside data collection on balance and mobility. The patient should then discuss their goals and expectations with the therapist.
The robot should be calibrated to provide walking assistance without fully taking over, ensuring that the patient‚Äôs muscles remain stimulated to generate their own strength. The therapist must closely monitor this process and adjust training parameters or treatment protocols as necessary to facilitate progress.
Physiotherapists working in rehabilitation centers will need specialized training to correctly operate this technology. Dedicated training courses should therefore be developed. Moreover, healthcare professionals specializing in Parkinson‚Äôs care should receive education on RAGT, for example, through ParkinsonNet, healthcare providers can enroll in training to become a Parkinson nurse specialist. Incorporating education on robotic rehabilitation into such curricula would ensure that professionals are well-prepared to implement RAGT effectively.

# 5. Monitoring implementation with effect and process evaluations
Chapter available in PDF


# 6. Conclusion
The number of patients with Parkinson‚Äôs disease is projected to almost triple by 2040 compared to current levels, largely due to population aging. It is therefore essential that more patients gain access to exercise-based therapies, as these have been shown to significantly improve both physical and mental health. A more efficient and future-proof therapeutic approach is urgently needed to meet this growing demand. Robot-Assisted Gait Training has been identified as a promising therapeutic option; evidence suggests that RAGT is at least as effective, and in some cases superior‚Äîto conventional physiotherapy in improving gait and balance among Parkinson‚Äôs patients. Furthermore, RAGT appears to be a cost-effective treatment, offering additional advantages such as safety, alignment with national fall-prevention policies, and consistent monitoring of patient progress. Nonetheless, the large-scale implementation of RAGT poses several challenges. Key stakeholders, including governments, insurers, patients, and healthcare professionals‚Äîmust be convinced of its cost-effectiveness, safety, and practical value. The acquisition and maintenance of robotic equipment require significant investment. While operational machines are generally less costly than wearable robots or exoskeletons, studies indicate that they can be equally or even more effective for lower-limb rehabilitation. Importantly, the effectiveness of RAGT depends on multiple adjustable gait parameters as well as the treatment protocol itself. Therapists must therefore receive comprehensive training to optimize parameter settings and ensure individualized treatment planning. Integrating RAGT into the education of specialized physiotherapists could support its successful adoption. Robotics should be regarded not as a replacement, but rather as a complement to conventional physiotherapy. Certain aspects of rehabilitation, such as transfer training, will continue to require traditional approaches. Collaboration with the patient remains essential in setting therapeutic goals and selecting appropriate exercises for RAGT. As RAGT is still a relatively novel intervention, existing research has not yet provided conclusive evidence regarding its effectiveness, feasibility, and acceptance by stakeholders. Pilot studies and large-scale clinical trials will therefore be necessary to evaluate its full potential. Current findings strongly suggest that robotics hold promise in improving mobility outcomes for patients with Parkinson‚Äôs disease, but further rigorous investigation is required before widespread implementation can be realized.

# References

1. NIH National Library of Medicine. *Parkinson's Disease.* [Online]. Available: [https://medlineplus.gov](https://medlineplus.gov). Accessed December 2022.  
2. C. Moreau, B. Barton, D. Devos. "Virtually reducing fall risk in Parkinson disease." *Neurology,* vol. 89, no. 17, pp. 1762‚Äì1763, 2017.  
3. Z. Galati. *Is Parkinson‚Äôs Fatal? What can I do about it?* Parkinson Foundation, Aug. 24, 2021. [Online]. Available: [https://parkinsonfoundation.org](https://parkinsonfoundation.org). Accessed December 2022.  
4. L. Kalia, A. Lang. "Parkinson's disease." *The Lancet,* vol. 386, no. 9996, pp. 896‚Äì912, Aug. 2015.  
5. L. de Lau, M. Breteler. "Epidemiology of Parkinson's disease." *The Lancet Neurology,* vol. 5, no. 6, pp. 525‚Äì535, Jun. 2006.  
6. E. Dorsey, T. Sherer, M. Okun, B. Bloem. "The Emerging Evidence of the Parkinson Pandemic." *Journal of Parkinson's Disease,* vol. 8, no. s1, pp. S3‚ÄìS8, 2018.  
7. CBS. *Medisch Specialistische Zorg; pati√´nten, diagnose, regio,* Nov. 10, 2017. [Online]. Available: [https://opendata.cbs.nl/#/CBS/nl/dataset/82223NED/table](https://opendata.cbs.nl/#/CBS/nl/dataset/82223NED/table). Accessed Jan. 2023.  
8. C.D.W.S. MV Lopez. "L-DOPA is an endogenous ligand for OA1." *PLOS Biology,* vol. 9, e236, 2008.  
9. M. Schenkman, C. Moore, W. Kohrt. "Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial." *JAMA Neurology,* vol. 75, no. 2, pp. 219‚Äì226, 2018.  
10. NHG. *Ziekte van Parkinson,* 2011. [Online]. Available: [https://richtlijnen.nhg.org/standaarden/ziekte-van-parkinson](https://richtlijnen.nhg.org/standaarden/ziekte-van-parkinson). Accessed Jan. 2023.  
11. KNGF. *KNGF richtlijn ziekte van Parkinson,* 2017. [Online]. Available: [link](https://www.parkinsonnet.nl/app/uploads/2019/11/informatie_over_ft_voor_mensen_met_parkinson.pdf). Accessed Jan. 20, 2023.  
12. A. Talebi, J. Ypinga, N. De Vries. "Specialized Versus Generic Allied Health Therapy and the Risk of Parkinson's Disease Complications." *Movement Disorders,* 2022.  
13. CBS. *Ouderen.* [Online]. Available: [https://www.cbs.nl/nl-nl/visualisaties/dashboard-bevolking/leeftijd/ouderen](https://www.cbs.nl/nl-nl/visualisaties/dashboard-bevolking/leeftijd/ouderen). Accessed Jan. 2023.  
14. G. Carpino, A. Pezzola, M. Urbano. "Assessing Effectiveness and Costs in Robot-Mediated Lower Limbs Rehabilitation: A Meta-Analysis and State of the Art." *Journal of Healthcare Engineering,* 2018.  
15. C. Sconza, F. Negrini, B. Di Matteo. "Robot-Assisted Gait Training in Patients with Multiple Sclerosis: A Randomized Controlled Crossover Trial." *Medicina (Kaunas, Lithuania),* vol. 57, no. 7, 2021.  
16. CBS. *Werkdruk en arbeidstevredenheid in de zorg,* Nov. 17, 2022. [Online]. Available: [https://www.cbs.nl/nl-nl/longread/statistische-trends/2022/werkdruk-en-arbeidstevredenheid-in-de-zorg](https://www.cbs.nl/nl-nl/longread/statistische-trends/2022/werkdruk-en-arbeidstevredenheid-in-de-zorg). Accessed Jan. 2023.  
17. Parkinson Vereniging. *Vergoeding fysiotherapie.* [Online]. Available: [https://www.parkinson-vereniging.nl/overig/informatiedossiers/zorgverzekering](https://www.parkinson-vereniging.nl/overig/informatiedossiers/zorgverzekering). Accessed Jan. 2023.  
18. Consumentenbond. *Vergoeding zorgverzekering Fysiotherapie.* [Online]. Available: [https://www.consumentenbond.nl/zorgverzekering/vergoedingen/fysiotherapie](https://www.consumentenbond.nl/zorgverzekering/vergoedingen/fysiotherapie). Accessed Jan. 2023.  
19. M. Capecci. "Clinical effects of robot-assisted gait training and treadmill training for Parkinson‚Äôs disease: A randomized controlled trial." *Annals of Physical and Rehabilitation Medicine,* vol. 62, pp. 303‚Äì312, 2019.  
20. A. Picelli. "Robot-assisted gait training versus equal intensity treadmill training in patients with mild to moderate Parkinson‚Äôs disease: A randomized controlled trial." *Parkinsonism and Related Disorders,* vol. 19, pp. 605‚Äì610, 2013.  
21. P. Gryfe, A. Sexton, C. McGibbon. "Using gait robotics to improve symptoms of Parkinson's disease: an open-label, pilot randomized controlled trial." *European Journal of Physical and Rehabilitation Medicine,* vol. 58, no. 5, pp. 723‚Äì737, 2022.  
22. S. Carda. "Robotic Gait Training is not Superior to Conventional Treadmill Training in Parkinson Disease: A Single-Blind Randomized Controlled Trial." *Neurorehabilitation and Neural Repair,* vol. 26, no. 9, pp. 1027‚Äì1034, 2012.  
23. K. van Kammen. "Amplitude and stride-to-stride variability of muscle activity during Lokomat guided walking and treadmill walking in children with cerebral palsy." *European Journal of Paediatric Neurology,* vol. 29, pp. 108‚Äì117, 2020.  
24. M. Maier, B. Ballester, P. Verschure. "Principles of Neurorehabilitation After Stroke Based on Motor Learning and Brain Plasticity Mechanisms." *Frontiers in Systems Neuroscience,* vol. 13, no. 74, 2019.  
25. T. Wagner, A. Lo, P. Peduzzi, D. Bravata. "An economic analysis of robot-assisted therapy for long-term upper-limb impairment after stroke." *Stroke,* vol. 42, no. 9, pp. 2630‚Äì2632, 2011.  
26. C. Fundar√≤, A. Giardini, R. Maestri, S. Traversoni. "Motor and psychosocial impact of robot-assisted gait training in a real-world rehabilitation setting: A pilot study." *PloS One,* vol. 13, no. 2, 2018.  
27. Zorginstituut Nederland. *Onderzoeksrapport: Implementatie van de leidraad 'Nieuwe interventies in de klinische praktijk',* Jul. 10, 2020. [Online]. Available: [link](https://www.zorginstituutnederland.nl/publicaties/rapport/2020/07/10/onderzoeksrapport-implementatie-van-de-leidraad-nieuwe-interventies-in-de-klinische-praktijk). Accessed Feb. 2023.  
28. S. Fricke. *Towards personalized robot-assisted gait training.* University of Twente, 2020.  
29. ParkinsonNet. *Opleiding tot Parkinsonverpleegkundige 2022/2023.* [Online]. Available: [link](https://mijn.parkinsonnet.nl/Webshop?id=a1C1v00000ArvSNEAZ). Accessed Feb. 2023.  
30. Zorginstituut Nederland. *Beoordeling van nieuwe zorg.* [Online]. Available: [https://www.zorginstituutnederland.nl/over-ons/werkwijzen-en-procedures/adviseren-over-en-verduidelijken-van-het-basispakket-aan-zorg/beoordeling-van-nieuwe-zorg](https://www.zorginstituutnederland.nl/over-ons/werkwijzen-en-procedures/adviseren-over-en-verduidelijken-van-het-basispakket-aan-zorg/beoordeling-van-nieuwe-zorg). Accessed Jan. 2023.  
31. S. Keus. *European Physiotherapy Guideline for Parkinson's disease.* KNFG/ParkinsonNet, Amersfoort, 2014.  
32. S. Spina, N. Cinone, S. Facciorusso. "Effectiveness of robotic balance training on postural instability in patients with mild Parkinson's disease: A pilot, single blind, randomized controlled trial." *Journal of Rehabilitation Medicine,* vol. 53, no. 2, Feb. 17, 2021.  
33. T. Toole, C. Maitland, E. Warren, M. Hubmann. "The effects of loading and unloading treadmill walking on balance, gait, fall risk, and daily function in Parkinsonism." *NeuroRehabilitation,* vol. 20, pp. 307‚Äì322, 2005.  
34. A. Picelli, M. Capecci, M. Filippetti, V. Varalta. "Effects of robot-assisted gait training on postural instability in Parkinson's disease: a systematic review." *European Journal of Physical and Rehabilitation Medicine,* vol. 57, no. 3, pp. 472‚Äì477, 2021.  
35. L. Koukolov√°. "Overview of the robotic rehabilitation systems for lower limbs." *Transfer inov√°ci√≠,* pp. 107‚Äì111, 2015.

# About
Written 03-02-2023
36. REHA STIM MEDTEC. *Gait Trainer GT II.* [Online]. Available: [https://reha-stim.com/gt-ii/](https://reha-stim.com/gt-ii/). Accessed Jan. 21, 2023.  

